Skip to main content
. 2020 Jul 15;22(8):43. doi: 10.1007/s11883-020-00860-w

Fig. 2.

Fig. 2

Pemafibrate in patients with impaired renal function. Treatment with pemafibrate (0.2–0.4 mg daily) led to substantial lowering of triglycerides (TG) and elevation of high-density lipoprotein cholesterol (HDL-C), with similar responses in patients with normal or impaired renal function. Data from Yokote et al. [64•]. eGFR estimated glomerular filtration rate